Analyzing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Curative Biotechnology (OTCMKTS:CUBTD)

Curative Biotechnology (OTCMKTS:CUBTD) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings and Valuation

This table compares Curative Biotechnology and Zentalis Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
Zentalis Pharmaceuticals	$67.43 million	4.37	-$137.06 million	($1.73)	-2.39

Curative Biotechnology has higher earnings, but lower revenue than Zentalis Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Curative Biotechnology and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	0.00
Zentalis Pharmaceuticals	1	4	1	1	2.29

Zentalis Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 20.77%. Given Zentalis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Curative Biotechnology.

Profitability

This table compares Curative Biotechnology and Zentalis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Risk & Volatility

Curative Biotechnology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.

Summary

Zentalis Pharmaceuticals beats Curative Biotechnology on 6 of the 8 factors compared between the two stocks.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.